Diffuse Large B-cell Lymphoma (DLBCL) | Norton Healthcare

Indication: Diffuse Large B-cell Lymphoma (DLBCL)

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL

Relapsed or Refractory

Line of Therapy: 2nd or 3rd line

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Molecular Templates, Inc.

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.